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Abstract: Metabotropic γ-aminobutyric acid (GABAB) receptors contribute to the control of network
activity and information processing in hippocampal circuits by regulating neuronal excitability and
synaptic transmission. The dysfunction in the dentate gyrus (DG) has been implicated in Alzheimer´s
disease (AD). Given the involvement of GABAB receptors in AD, to determine their subcellular
localisation and possible alteration in granule cells of the DG in a mouse model of AD at 12 months
of age, we used high-resolution immunoelectron microscopic analysis. Immunohistochemistry at
the light microscopic level showed that the regional and cellular expression pattern of GABAB1 was
similar in an AD model mouse expressing mutated human amyloid precursor protein and presenilin1
(APP/PS1) and in age-matched wild type mice. High-resolution immunoelectron microscopy revealed
a distance-dependent gradient of immunolabelling for GABAB receptors, increasing from proximal
to distal dendrites in both wild type and APP/PS1 mice. However, the overall density of GABAB
receptors at the neuronal surface of these postsynaptic compartments of granule cells was significantly
reduced in APP/PS1 mice. Parallel to this reduction in surface receptors, we found a significant
increase in GABAB1 at cytoplasmic sites. GABAB receptors were also detected at presynaptic sites in
the molecular layer of the DG. We also found a decrease in plasma membrane GABAB receptors in
axon terminals contacting dendritic spines of granule cells, which was more pronounced in the outer
than in the inner molecular layer. Altogether, our data showing post- and presynaptic reduction
in surface GABAB receptors in the DG suggest the alteration of the GABAB-mediated modulation
of excitability and synaptic transmission in granule cells, which may contribute to the cognitive
dysfunctions in the APP/PS1 model of AD.
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1. Introduction
The dentate gyrus (DG) is an integral part of the hippocampal formation and play key roles in the
formation of episodic memory, spatial memory and exploration of new environments [1]. To fulfil
these functions, the DG is highly organised and numerous synaptic connections take place between
granule cells and basket cells, the principal cells and the primary inhibitory interneuron of the DG,
respectively [1,2]. The major input of the DG arises from entorhinal cortex layer II neurons through
the perforant path, and the functional integrity of this connection is necessary to fulfil its function in
memory formation and spatial navigation [3]. Therefore, dysfunction in this entorhinal cortex–dentate
gyrus pathway has been implicated in pathological conditions like Alzheimer´s disease (AD), the most
prevalent neurodegenerative disease in the elderly population.
During progression of AD, neurodegeneration begins in the entorhinal cortex and then propagates
to the adjacent regions, starting in the DG [4]. The three major neuropathology hallmarks of AD are
extracellular fibrillary amyloid beta peptide (Aβ) in amyloid plaques, intraneuronal neurofibrillary
tangles consisting of aggregated hyperphosphorylated tau and synapse loss [5]. Only loss of synapses
has been correlated with cognitive decline and proposed to underlie learning and memory deficits
in AD [6]. The vast majority of synapses in the DG of the hippocampus are glutamatergic excitatory
synapses, and the main targets of these synapses are the dendritic spines of granule cells. Given the
critical role of dendritic spines in memory, learning, and cognition, the loss of dendritic spines has been
reported in the DG in AD [7–9] and in the APP/PS1 mouse model [10]. In addition, an impairment of
adult neurogenesis has been reported in the DG in AD patients [11].
Granule cells in the DG are inhibited by γ-aminobutyric acid (GABA) synaptically released by
interneurons. The response to GABA is mediated by activation of both ionotropic (GABAA) and
metabotropic (GABAB) receptors [12,13]. The activation of GABAB receptors is coupled to intracellular
signal transduction mechanisms via G-proteins, mediating slow and prolonged synaptic inhibition
through the activation of postsynaptic inwardly rectifying K+ channels and inhibition of presynaptic
voltage-gated Ca2+ channels [13,14]. Acting on these effector ion channels, GABAB receptors have
modulatory actions on neuronal excitability and neurotransmitter release, and are involved in a number
of physiological and pathophysiological processes [13]. Growing evidence supports the involvement
of GABAB receptors in AD [15–19].
Two different cDNAs encoding GABAB receptor subunits have been cloned to date: GABAB1 and
GABAB2 [20,21]. Both receptor subunits are required to form functional receptors, with the GABAB1
subunit being necessary for agonist activation and the GABAB2 subunit for surface trafficking and
G-protein coupling [22–25]. Previous studies using different technical approaches showed that all
sub-regions of the hippocampus, including the DG, express a high density of GABAB receptors [20,26–28].
Immunoelectron microscopic studies demonstrated the main post- and pre-synaptic association of
GABAB receptors, mainly with excitatory synapses in dendritic spines of CA1 pyramidal cells and
granule cells of the DG [28–31]. In addition, we have recently reported a dramatic reduction in GABAB
receptors along the postsynaptic plasma membrane of CA1 pyramidal cells, as well as at presynaptic
sites in the excitatory synapses between Schaffer collateral-CA1 pyramidal cell spines in APP/PS1
mice [17]. Whether this alteration takes place in other principal cells of the hippocampus, such as
granule cells, in the AD model mice is not yet known.
Given the loss of dendritic spines and excitatory synapses in the DG in APP/PS1 mice [10], it is
expected that GABAB receptors are also affected. Therefore, to identify possible alterations in the
cellular and subcellular localisation of GABAB receptors in this mouse model, we used high-resolution
immunohistochemical techniques in combination with quantitative approaches at 12 months of age, a
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time when these animals show a large density of senile plaques and cognitive impairments [32,33] and
when GABAB receptors are altered along the surface of CA1 pyramidal cells [17]. Our data demonstrate
for the first time a significant reduction in the surface expression of GABAB receptors in the granule
cells of the DG in APP/PS1 mice.
2. Results
2.1. Regional and Cellular Distribution of GABAB1 in the DG of Control and APP/PS1 Mice
We first investigated the regional and cellular distribution of GABAB1 in the DG in wild type and
APP/PS1 mice at 12 months of age, using light microscopy immunohistochemical techniques (Figure 1).
In both genotypes, immunoreactivity for GABAB1 was the highest in the molecular layer, weak in the
hilus and weakest in the granule cell layer of the DG (Figure 1A–H). At the cellular level, GABAB1
immunoreactivity was weekly detected in the somata of granule cells but strongly expressed on their
dendrites in the molecular layer at their default dendritic localisation (Figure 1C,D,F,G). GABAB1
immunoreactivity was also observed on basket cells, a type of GABAergic interneuron located along
the interface between the granule cell layer and the polymorphic layer of the hilus (Figure 1D,G). In the
hilus, hilar neurons were intensely labelled for GABAB1, showing somatic expression of the subunit
(Figure 1E,H). The accumulation of Aβ in APP/PS1 mice was high throughout the molecular layer of
the DG, and particularly high in the outer two thirds of this layer compared to age-matched wild type
mice (Figure 1I,J). In spite of the large accumulation of Aβ in the DG of APP/PS1 mice, the regional and
cellular distributions for GABAB1 were very similar between wild and APP/PS1 mice (Figure 1A–H).
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2.2. Reduction in GABAB1 in the Postsynaptic Cell Surface of Granule Cells in APP/PS1 Mice
We recently reported that GABAB receptors are altered in CA1 pyramidal cells in the APP/PS1
mouse model of AD at 12 months of age [17]. To investigate whether other principal cells of the
hippocampus are also affected, we used the highly sensitive sodium dodecyl sulfate (SDS)-digested
freeze-fracture replica labeling (SDS-FRL)method [34]. To unravel the organisation of GABAB along the
surface of granule cells, the subcellular localisation of GABAB1 was investigated in sections of the DG
obtained from wild type and APP/PS1 mice at 12 months of age. Using our ultrastructural approach,
we detected immunoparticles for GABAB1 along the plasma membrane of the entire somato-dendritic
compartment of granule cells, both in wild type (Figure 2) and APP/PS1 mice (Figure 3), but with
notable quantitative differences (Figure 4) as described below.
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(*). The E-face is free of any immunolabelling. Scale bars: A–F, 0.2 µm.
In wild type mice, immunoparticles for GABAB1 were abundantly detected in dendritic spines
and dendritic shafts throughout the molecular layer, and also in the somata of granule cells in the
granule cell layer (Figure 2A–F). In the six neuronal compartments of granule cells analysed, GABAB1
immunoparticles were found forming clusters (an aggregation of more than three gold particles) or
scattered (one or two isolated gold particles) (Figure 2A–F). Most immunoparticles were observed in
clusters and less frequently scattered in the somata (Figure 2A) and dendritic compartments in the
inner one third (Figure 2B–D) and outer two thirds (Figure 2E,F) of the molecular layer. Virtually no
labelling was observed on the E-face or on cross-fractures (Figure 2A–F).
In APP/PS1 mice, GABAB1 immunoparticles were observed in dendritic spines, dendritic shafts
and somata of granule cells (Figure 3A–F). However, the intensity of GABAB1 changed significantly in
the six neuronal compartments of granule cells analysed. Fewer immunoparticles per cluster and fewer
clustered and scattered immunoparticles were detected along the neuronal surface of DG granule
cells (Figure 3A–F). Similarly, as with the wild type, no labelling was observed on the E-face or on
cross-fractures in APP/PS1 mice (Figure 3A–F).
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Figure 4. Density gradient of GABAB1 immunoparticles along the surface of granule cells in wild
type and APP/PS1 mice at 12 months. Quantitative analysis of GABAB1 immunogold labelling in six
neuronal compartments of DG granule cells. The density gradient of immunoparticles for GABAB1
along the neuronal surface was significantly reduced in all subfields and compartments of granule cells
analysed in the APP/PS1 mice compared to age-matched wild type (Two-way ANOVA test F(1,192) =
70.78, p < 0.0001 (genotype) and Bonferroni post-hoc test, * p < 0.05; ** p < 0.01; *** p < 0.001). Error
bars indicate SEM. Abbreviations: PriDen, primary dendrite; SecDen, secondary dendrite; s, spine;
SM, soma.
Next, we performed a quantitative comparison of the GABAB1 densities in the six different
somato-dendritic compartments of granule cells (Figure 4). In wild type, this analysis showed that
GABAB1 was not evenly distributed along the neuronal surface in granule cells, but, instead, there was
a graded increase in the density of GABAB1 immunoparticles from the soma to the dendritic spines
(Figure 4). This distribution gradient was also detected in granule cells from APP/PS1 mice (Figure 4).
Int. J. Mol. Sci. 2020, 21, 2459 6 of 18
However, our analysis demonstrated that GABAB1 density along the neuronal surface was significantly
reduced in all compartments analysed in granule cells of the APP/PS1 mice compared to age-matched
control mice at 12 months of age (two-way ANOVA test F(1,192) = 70.78, p < 0.0001 (genotype) and
Bonferroni post-hoc test, * p < 0.05; ** p < 0.01; *** p < 0.001) (Figure 4).
2.3. Reduction in Presynaptic GABAB1 in the Dentate Gyrus of APP/PS1 Mice
In addition to somato-dendritic domains of DG granule cells, immunoparticles for GABAB1 were
also detected presynaptically in axon terminals, consistent with previous reports [28–31]. Therefore,
we next investigated whether the subcellular distribution of GABAB1 at presynaptic sites is altered in
the inner one third and outer two thirds of the DG molecular layer of APP/PS1 at 12 months of age
using the SDS-FRL technique (Figure 5). In wild type mice, immunoparticles for GABAB1 were found
forming clusters and scattered outside the clusters in active zones of axon terminals, as well as along
the extrasynaptic site of axon terminals, both in the outer two thirds (Figure 5A) and inner one third
(Figure 5D) of the DG molecular layer. The density of immunoparticles for GABAB1 was higher at
the active zones (AZ; inner one third = 288.12 ± 50.29 immunoparticles/µm2, n = 269 particles; outer
two thirds = 379.49 ± 36.27 immunoparticles/µm2, n = 667 particles) than at extrasynaptic sites (Extra;
inner one third = 41.28 ± 11.14 immunoparticles/µm2, n = 144 particles; outer two thirds = 28.77 ± 6.44
immunoparticles/µm2, n = 200 particles) (Figure 5C,F). In APP/PS1 mice, immunoparticles for GABAB1
showed the same presynaptic distribution in the outer two thirds (Figure 5B) and inner one third
(Figure 5E) of the DG molecular layer than that described in wild type mice. However, quantitative
comparisons with age-matched wild type mice showed significant differences in the density of GABAB1
immunoparticles in the active zone and extrasynaptic sites in the outer two thirds (AZ = 121.30 ± 18.01
immunoparticles/µm2, n = 76 particles; Extra = 7.86 ± 2.16 immunoparticles/µm2, n = 33 particles)
(Figure 5C), and in the inner one third (AZ = 179.54 ± 37.06 immunoparticles/µm2, n = 116 particles;
Extra = 7.67 ± 1.95 immunoparticles/µm2, n = 33 particles) (Figure 5F) (for AZ, Two-way ANOVA test
F(1,69) = 26.48, p < 0.0001 (genotype) and Bonferroni post-hoc test, * p < 0.05; **** p < 0.0001; and for
extrasynaptic Two-way ANOVA test F(1,69) = 17.09, p < 0.0001 (genotype) and Bonferroni post-hoc test,
** p < 0.01).. In the two portions of the molecular layer, the reduction in the density of GABAB1 was
higher in the outer two thirds than in the inner one third (Figure 5C,F), suggesting an input-dependent
alteration of GABAB receptors.
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Figure 5. Presynaptic distribution of GABAB1 in the dentate gyrus in wild type and APP/PS1 mice.
Electron micrographs showing immunoparticles for GABAB1 in presynaptic compartments in the outer
two thirds (ml o2/3) and inner one third (ml i1/3) of the molecular layer of the DG at 12 months of age,
Int. J. Mol. Sci. 2020, 21, 2459 7 of 18
as detected using the SDS-FRL technique. (A,D) In wild type, immunoparticles for GABAB1 were
found forming clusters (blue ellipses/circles) and also detected scattered (purple arrows) outside
the clusters within the active zone (az, blue transparent overlay) and along the extrasynaptic site of
axon terminals (ax). (B,E) In APP/PS1, fewer immunoparticles for GABAB1 forming clusters (blue
ellipses/circles) or scattered (purple arrows), were detected within the active zone (az, red transparent
overlay) and along the extrasynaptic plasma membrane of axon terminals (ax). Cross-fractures are
indicated with asterisks (*). (C,F) Histograms illustrating densities of immunoparticles for GABAB1
in presynaptic compartments in the outer two thirds (ml o2/3) and inner one third (ml i1/3) of the
molecular layer in wild type and APP/PS1 mice. Significant differences were detected in densities
of GABAB1 immunoparticles in the outer two thirds of the molecular layer (Wild type: Active zone
(AZ) = 379.49 ± 36.27 immunoparticles/µm2 and Extra = 28.77 ± 6.44 immunoparticles/µm2; APP/PS1:
AZ = 121.31 ± 18.01 immunoparticles/µm2; Extra = 7.87 ± 2.16 immunoparticles/µm2), as well as in the
inner one third of the molecular layer (Wild type: AZ = 288.12 ± 50.29 immunoparticles/µm2 and Extra
= 41.28 ± 11.14 immunoparticles/µm2; APP/PS1: AZ = 179.54 ± 37.06 immunoparticles/µm2; Extra =
7.67 ± 1.94 immunoparticles/µm2) (for AZ, Two-way ANOVA test F(1,69) = 26.48, p < 0.0001 (genotype)
and Bonferroni post-hoc test, * p < 0.05; **** p < 0.0001; and for extrasynaptic Two-way ANOVA test
F(1,69) = 17.09, p < 0.0001 (genotype) and Bonferroni post-hoc test, ** p < 0.01). Error bars indicate SEM.
Scale bars: A,D, 0.2 µm; B,E, 0.5 µm.
2.4. GABAB1 Is Increased in the Cytoplasm of Granule Cells in APP/PS1 Mice
Finally, to explore the possibility that the reduction in GABAB1 along the membrane surface is
due to its internalisation and accumulation at intracellular sites of granule cells and axon terminals of
APP/PS1 mice at 12 months of age, we used the pre-embedding immunogold technique and quantitative
analysis on tissue blocks taken from the inner molecular layer of the DG, where larger differences were
detected in the density for GABAB1 between wild type and APP/PS1 mice.
Postsynaptically, immunoparticles for GABAB1 were found along the extrasynaptic plasma
membrane of dendritic spines and shafts of granule cells, as well as associated at intracellular sites
in the same neuronal compartments, both in wild type and APP/PS1 mice (Figure 6). Quantitative
analysis showed differences in the plasma membrane versus intracellular sites in the molecular layer
(plasma membrane: 42.81% in wild type, n = 286 particles, and 18.58% in APP/PS1, n = 943 particles;
intracellular: 57.19 % in wild type, n = 382 particles, and 81.42% in APP/PS1, n = 3224 particles) of the
DG (Figure 6E). This change in the plasma membrane versus the intracellular membrane labelling was
detected both in dendritic spines (plasma membrane: 56% in wild type, n = 98 particles, and 35.09% in
APP/PS1, n = 189 particles; intracellular: 44% in wild type, n = 77 particles, and 64.90% in APP/PS1,
n = 342 particles) and dendritic shafts (plasma membrane: 39.77% in wild type, n = 171 particles, and
16.17% in APP/PS1, n = 442 particles; intracellular: 60.23% in wild type, n = 259 particles, and 83.83%
in APP/PS1, n = 2278 particles) (Figure 6E). Presynaptically, immunoreactivity for GABAB1 was also
detected in axon terminals establishing asymmetrical synapses with the dendritic spines of granule
cells (Figure 6A–D). The quantitative analysis showed changes in the plasma membrane versus the
intracellular membrane among wild type and APP/PS1 in the molecular layer (plasma membrane:
26.98% in wild type, n = 17 particles, and 7.65% in APP/PS1, n = 26 particles; intracellular: 73.01% in
wild type, n = 46 particles, and 92.34% in APP/PS1, n = 222 particles) (Figure 6E).
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Figure 6. Intracellular distribution of i i creased in the DG of APP/ S1 mice. El ctron
micrographs showing i munoparticles for GABAB1 in granule cells of the inner molecular layer of
the DG at 12 months of age in wild type and APP/PS1 mice, as detected using a pre-embedding
immunogold technique. (A–D) Both in wild type and APP/PS1 mice, GABAB1 immunoparticles were
found along the extrasynaptic plasma membrane (arrows) and intracellular sites (crossed arrows)
of dendritic shafts (Den) and spines (s) of granule cells contacted by axon terminals (at), and less
frequently at presynaptic sites (arrowheads). (E) Quantitative analysis showed that immunoparticles
for GABAB1 were less frequently observed along the extrasynaptic plasma membrane dendrites and
spines of granule cells in PP/PS1 mice, as well at presynaptic sites, but, instead, they were more
frequently detected at intracellular sites. Scale bars: A–D, 0.4 µm.
3. Discussion
The present study provides the first detailed description on the 2D mapping of GABAB receptors
along the neuronal surface of DG granule cells, with particular emphasis on their possible alteration in
a mouse model of Alzheimer´s disease. Using light microscopy, we showed that GABAB1 receptors
are widely distributed throughout the different areas of the DG with similar expression intensity and
patterns in both wild type and APP/PS1 mic . However, using the SDS-FRL method, our data reveal a
decrease in GABAB receptors along the plasma membrane of all subcellular post ynaptic compartments,
and a parallel increase at intracellular sites, in DG granule cells at 12 months of age. We additionally
reveal a decrease in presynaptic GABAB receptors in axon terminals in the commissural/associational
inputs and the entorhinal inputs, both contacting granule cells in a segregated manner. These
reductions in postsynaptic and presynaptic GABAB receptors likely contribute to the pathology and
memory impairment described in the APP/PS1 model of AD, providing new insights to understand
the pathological events taking place in the disease.
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3.1. Cellular Distribution of GABAB Receptors in the Mouse Model of AD
Dysfunction of the GABAergic system contributes to the modulation of learning and memory
mechanism and function [35,36]. Accordingly, the inhibition of GABAB receptors improves learning
and memory formation [37,38] and altered GABAB receptor function has been involved in AD
pathogenesis [39]. Previous autoradiographic, in situ hybridisation and immunohistochemical reports
showed that DG contains high levels of GABAB receptors [20,26,28,29]. At the cellular level, granule cells
express transcripts for both GABAB1a and GABAB1b subunits [27], although they are targeted to different
synaptic sites to perform distinct functions [30]. Thus, mossy fibre terminals are immunopositive for
the GABAB1a subunit, whereas dendrites of granule cells are immunopositive for GABAB1b [30,40].
In the present study, we used a pan-GABAB1 antibody and, therefore, it was not possible to differentiate
between the expression and distribution of both GABAB1a and GABAB1b subunits in granule cells.
However, immunoreactivity for the GABAB receptor subunit was predominantly enriched in the
molecular layer of the DG, suggesting a mainly dendritic localisation.
Growing evidence shows that dysfunction of GABAB-mediated synaptic transmission underlies
a number of disorders in the brain [39,41–43]. Given the role of GABAB receptors in learning
and memory [37,42], their involvement in AD has also been suggested. Supporting this idea,
recent studies reported not only that GABAB receptors selectively co-purify with APP [15], but also
that GABAB-APP macromolecular complexes link presynaptic GABAB receptor trafficking to Aβ
formation [16]. In addition, autoradiography studies of GABAB receptor expression in the human
hippocampus of AD patients demonstrated fewer GABAB receptors in the molecular layer of the
dentate gyrus [44]. Here, we described that the regional and cellular distribution of GABAB receptors
in the DG is virtually identical in APP/PS1 and control mice. Similarly, we have recently described that
the expression of GABAB receptors does not change in the CA1 and CA3 regions of the hippocampus in
the same mouse model of AD, although expression is significantly reduced in the human hippocampus
of AD patients [17].
These discrepancies could be likely due to differences in brain organisation between humans
and mice [45], to the fact that the APP/PS1 model does not develop neurofibrillary tangles, a typical
pathologic alteration observed in AD patients [46], or simply because the age of 12 months old used
here, as well as by other laboratories, is still too short to detect gross changes. However, this mouse
model shows reduced number of synapses per volume and the synaptic morphology in plaque-free
regions of the DG outer molecular layer [10], and thus it is useful to detect possible alterations of
synapse-associated receptors and/or ion channels [17].
3.2. Altered Somato-Dendritic Localisation of GABAB Receptors in APP/PS1 Granule Cells
Using the SDS-FRL technique, we detected the majority of postsynaptic GABAB1 immunoparticles
along the extrasynaptic membrane of dendritic spines and shafts of granule cells, consistent with
our immunoreactions at the light microscopic level. GABAB receptors localised to postsynaptic
sites activate G protein-gated inwardly rectifying K+ (GIRK) channels and are responsible for the
slow inhibitory postsynaptic potentials IPSP [47,48], and GABAB receptor-mediated slow inhibitory
responses have been found in granule cells [31,49–52]. The prevalent localisation of GABAB1 in spines
and dendrites we revealed here is in agreement with those electrophysiological observations showing
the postsynaptic role of GABAB receptors in granule cells. Interestingly, GIRK channels show a very
similar somato-dendritic distribution than GABAB receptors [31], suggesting that those GABAB-GIRK
signalling cascade controls excitability in granule cell membranes.
The laminar arrangement of the cell bodies of granule cells in the DG allowed us to investigate
changes in the density of GABAB receptors in dendritic spines as a function of distance from the soma
in wild type and APP/PS1 mice. The molecular layer is occupied mainly by the dendritic arbour
of granule cells, as well as axons and terminal axonal arbours from the entorhinal cortex and other
sources. Granule cells receive a major input from cells located in layer II of the entorhinal cortex, via the
so-called perforant pathway. The entorhinal terminals are strictly confined to the outer two-thirds of
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the molecular layer where they form asymmetric synapses with spines of granule cells [53]. Inputs
forming the commissural/associational pathway are limited to the inner one third of the molecular
layer and largely contain axon terminals from the ipsilateral and contralateral hippocampus [53].
Given this anatomical organisation, quantitative comparison of immunogold densities revealed
the distance- and subcellular compartment-specific distribution pattern of GABAB receptors on the
surface of granule cells. Our high-resolution immunolocalisation experiments showed an increase in
immunolabelling for GABAB1 from proximal to distal dendrites. Consistent with our morphological
data, electrophysiological studies have shown that GABAB receptor-mediated currents are significantly
larger in dendrites than in the somata of granule cells, and were markedly higher for the distal
primary dendrites in the outer molecular layer [31]. Interestingly, GIRK channels show a very similar
somato-dendritic distribution than GABAB receptors [31], suggesting that the GABAB-GIRK signalling
cascade controls excitability in granule cell membranes.
In APP/PS1 mice, our analysis, performed at 12 months of age, also revealed distance-dependent
and subcellular compartment-specific localisation of GABAB receptors in granule cells. However,
the main finding of this study is the significant reduction in the membrane surface distribution of
GABAB receptors in all subcellular compartments of granule cells. These findings are consistent with
the evidence that the density of binding sites for GABAB receptors is decreased in molecular layer
of the DG in human hippocampus with AD [44]. In addition, parallel to the decrease in the density
of GABAB1 along the membrane surface, the application of different immunoelectron microscopy
and quantitative analyses showed that there is an accumulation of immunoparticles at cytoplasmic
sites in the dendrites and spines of granule cells. This pool of internalised GABAB receptors does not
seem to be redirected to lysosomal degradation in AD, not yet, at least, at 12 months of age. A similar
internalisation has been recently described in CA1 pyramidal cells in the same mouse model [17],
suggesting that different principal cells in the hippocampus use similar mechanisms to remove GABAB
receptors from the plasma membrane.
3.3. Altered Presynaptic GABAB Receptors in the Molecular Layer of APP/PS1 Mice
In addition to the main presence of GABAB1 in somato-dendritic compartments of granule cells, we
also found presynaptic labelling for this receptor subunit in the axon terminals establishing excitatory
synapses in the molecular layer of the DG. Presynaptic labelling for GABAB receptors has been
described in other regions of the hippocampus, including the CA1 and CA3 subfields [17,28–30,54].
Presynaptic activation of GABAB receptors mediate slow and prolonged synaptic inhibition by
inhibiting voltage-activated calcium (Cav) channels to result primarily in reduced vesicular release of
neurotransmitter [13]. Using the SDS-FRL technique, we observed immunoparticles for GABAB1 along
the extrasynaptic membrane and the active zone of axon terminals located both in the outer two thirds
and inner one third of the molecular layer, in agreement with previous studies using pre-embedding
immunogold techniques [28,29]. However, in the mouse model of AD we not only found a reduction
in the density of GABAB receptors in the inner and outer molecular layer, but also that the decrease
was strongest in the termination area of the perforant pathway. Overall, these results are in good
agreement with studies showing that the increase in Aβ production is linked to dysfunctional axonal
trafficking and to the reduction in the expression of GABAB receptor in the APP knockout mice [16].
The functional consequences of this input-dependent reduction in GABAB receptors is not yet
known, but our data agrees with previous reports showing that AD pathology begins in the entorhinal
cortex and spreads through the perforant pathway to the hippocampus [55]. Since the DG is a
hippocampal region with a large accumulation of Aβ in AD [56], the larger decrease in the density
of presynaptic GABAB receptors in the outer two thirds of the molecular layer may reflect changes
due to entorhinal cortical pathology. However, since the perforant pathway lacks strong presynaptic
GABAB receptor-mediated inhibition [57], the main effect produced by the reduction in GABAB
receptor expression in the APP/PS1 mice mostly arises from postsynaptic receptors. Altogether,
given the cognitive deficits observed in APP/PS1 mice [58], the pre- and post-synaptic reduction in
Int. J. Mol. Sci. 2020, 21, 2459 11 of 18
GABAB receptors in granule cells, together with the alterations affecting other principal cells of the
hippocampus [17], may represent the molecular and anatomical substrate of the altered cognitive
function observed in this mouse model of AD. Supporting this idea, it has been shown that CGP55845,
an antagonist of GABAB receptors, restored the memory of mice and augmented LTP [59]. More recently,
the use of a different GABAB receptor antagonist, CGP35348, showed beneficial effects in improving
cognition, learning, and memory in memory tests in acute Aβ toxicity-induced rats [60]. These data
indicate that potential therapeutics may target GABAB receptors in the hippocampus.
4. Material and Methods
4.1. Animals
The mouse line used for this study (APP/PS1; hemizygote animals) expressed the Mo/Hu
APP695swe construct in conjunction with the exon-9-deleted variant of human presenilin 1
(PS1-dE9) [61]. Control mice were age-matched littermates without the transgene (wild type). Mice of
all genotypes were aged to 12 months before use in a battery of morphological experiments. For each
genotype, four mice were used for SDS-FRL techniques, three mice were used for immunohistochemistry
at the light microscopic level and three mice were used for pre-embedding immunoelectron microscopic
analyses. All mice were obtained from the Animal House Facility of the University of Castilla–La
Mancha (Albacete, Spain). Animals were housed in cages of two or more mice, maintained on a 12 h
light/12 h dark cycle at 24◦C and received food and water ad libitum. Both the care and handling of
animals prior to and during experimental procedures were carried out in accordance with Spanish (RD
1201/2015) and European Union regulations (86/609/EC), and the protocols were approved (22 March
2019) by the local Animal Care and Use Committee.
For immunohistochemistry at the light and electron microscopic levels, animals were deeply
anaesthetised by intraperitoneal injection of ketamine-xylazine 1:1 (0.1 mL/kg) or sodium pentobarbital
(50 mg/kg, i.p.) and transcardially perfused with ice-cold fixative containing 1) 2% paraformaldehyde
in 0.1 M phosphate buffer (PB, pH 7.4) for 12 min (for SDS-FRL technique), or 2) 4% paraformaldehyde,
0.05% glutaraldehyde, and 15% (v/v) saturated picric acid made up in 0.1 M phosphate buffer (PB),
pH 7.4 (for light microscopy and pre-embedding immunogold techniques). After perfusion, these
brains were removed and coronal sections were cut on a Vibratome (Leica VT1000).
4.2. Antibodies and Chemicals
In the present study, we used the following primary antibodies: 1) An affinity-purified rabbit
polyclonal antibody representing the amino acid sequence of GABAB1 (ref#B17, residues 901–960 of rat
GABAB1). This antibody has been characterised and the specificity proven elsewhere [30,62,63]; and 2)
An affinity-purified rabbit polyclonal antibody anti-β amyloid (ref #2454, detecting both human Aβ-40
and Aβ-42 peptides; Cell Signalling Technology, Leiden, The Netherlands). In addition, we used the
following secondary antibodies: alkaline phosphatase (AP)-goat anti-rabbit IgG (H+L) diluted 1:5000
(Invitrogen, Paisley, UK), goat anti-rabbit IgG coupled to 1.4 nm gold diluted 1:100 (Nanoprobes Inc.,
Stony Brook, NY, USA) and anti-rabbit IgG conjugated to 10 nm gold particles diluted 1: 100 (British
Biocell International, Cardiff, UK).
4.3. Immunohistochemistry for Light Microscopy
The immunoperoxidase method was chosen to perform immunohistochemical reactions at the
light microscopic level, as we described in detail previously [64]. Hippocampal sections were incubated
for one hour in 10% normal goat serum (NGS) diluted in 50 mM Tris buffer (pH 7.4) containing 0.9%
NaCl (TBS) and 0.2% Triton X-100. After several washes in TBS, hippocampal sections were incubated
in the primary antibody (anti-GABAB1 or anti-β amyloid, both at a concentration of 1–2 µg/mL and
diluted in TBS containing 1% NGS). Next, the sections were incubated in biotinylated goat anti-rabbit
IgG (Vector Laboratories, Burlingame, CA, USA) diluted 1:200 in TBS containing 1% NGS, and then
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transferred into avidin–biotin–peroxidase complex (ABC kit, Vector Laboratories). Next, we revealed
peroxidase enzyme activity using the chromogen 3,3´-diaminobenzidine tetrahydrochloride (DAB;
0.05% in TB, pH 7.4) and the substrate H2O2 (0.01% in distilled water). Hippocampal sections were then
air-dried for few hours, mounted in DPX (Merk, Darmstadt, Germany), coverslipped and observed in
a Leica photomicroscope (DM2000) equipped with differential interference contrast optics and a digital
camera (DFC500).
4.4. Immunohistochemistry for Electron Microscopy
The pre-embedding immunogold and the SDS-digested freeze-fracture replica labelling (SDS-FRL)
techniques were chosen to perform immunohistochemical reactions at the electron microscopic level,
as we described in detail previously [34,64,65].
4.4.1. Pre-Embedding Immunogold Method
Hippocampal sections obtained from both WT and APP/PS1 mice at 12 months of age were
incubated in 10% NGS diluted in TBS.
After several washes in TBS, hippocampal sections were incubated in the primary antibody
(anti-GABAB1 at a concentration of 3–5 µg/mL and diluted in TBS containing 1% NGS). After several
washes in TBS, the sections were incubated in goat anti-rabbit IgG coupled to 1.4 nm gold (Nanoprobes
Inc., Stony Brook, NY, USA). Next, hippocampal sections were postfixed in 1% glutaraldehyde, washed
in double-distilled water and silver enhancement of the gold particles (HQ Silver kit, Nanoprobes Inc.).
Following treatment with osmium tetraoxide (1% in 0.1 M phosphate buffer), block-staining with uranyl
acetate and dehydration in graded series of ethanol, the sections were then flat-embedded on glass slides
in Durcupan (Fluka) resin. After polymerization of the resin, regions of interest were cut at 70–90 nm
on an ultramicrotome (Leica EM UC7, Leica, Wetzlar, Germany) and collected on pioloform-coated
copper grids. Finally, ultrathin sections were stained on drops of 1% aqueous uranyl acetate and
Reynolds’s lead citrate. For ultrastructural analyses we used a JEOL-1010 electron microscope.
4.4.2. SDS-FRL Technique
Mice brains were perfused using 2% paraformaldehyde in 0.1 M phosphate buffer (PB) for 12 min.
Following several washes in 0.1 M PB, the hippocampus was dissected and cut sagittal (130 µm-thick
sections) using a Microslicer (Dosaka, Kyoto, Japan). Hippocampal sections containing the DG were
further trimmed down, immersed in graded glycerol of 10%–30% in 0.1 M PB at 4 ◦C overnight, and
frozen using a high-pressure freezing machine (HPM010, BAL-TEC, Balzers, Liechtenstein). Next, DG
slices were fractured into two parts at−120 ◦C and then replicated by depositions of carbon (5 nm-thick),
platinum (60◦ unidirectional from horizontal level, 2 nm-thick), and carbon (15–20 nm-thick) using
a freeze-fracture replica machine (BAF060, BAL-TEC, Balzers). The resulting replicas were then
transferred to 2.5% SDS and 20% sucrose in 15 mM Tris buffer (pH 8.3) for 18 h at 80 ◦C with shaking,
washed three times in 50 mM TBS (pH 7.4) containing 0.05% bovine serum albumin (BSA), and blocked
with 5% BSA for 1 h at room temperature. After several washes in TBS containing 0.05% BSA, replicas
were incubated in a polyclonal rabbit antibody for GABAB1 (5 µg/mL) at 15 ◦C overnight. Next, replicas
were blocked in 5% BSA/TBS and incubated in secondary antibodies conjugated with 10 nm gold
particles overnight at room temperature. Finally, the replicas were rinsed with 0.05% BSA in TBS,
washed with distilled water, and picked up onto grids coated with pioloform (Agar Scientific, Stansted,
Essex, UK). For ultrastructural analyses, we used a JEOL-1010 electron microscope.
4.5. Quantification and Analysis of SDS-FRL Data
The labelled replicas were examined using a transmission electron microscope (JEOL-1010) and
photographed at magnifications of 60,000, 80,000, and 100,000×. All antibodies used in this study
were visualised by immunoparticles on the protoplasmic face (P-face), consistent with the intracellular
location of their epitopes. Non-specific background labelling was measured on E-face surfaces in wild
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type mice. Digitised images were then modified for brightness and contrast using Adobe PhotoShop
CS5 (Mountain View, CA, USA) to optimise them for quantitative analysis of immunolabelling.
The quantitative analyses were done using the software Gold Particle Detection and Quantification
(GPDQ), developed recently to perform automated and semi-automated detection of gold particles
present in a given compartment of neurons [34].
Density Gradient of GABAB1 along the Neuronal Surface
The procedure was similar to that used previously [34]. Briefly, immunogold labelling for GABAB1
was achieved from replicas containing all three layers of the DG, so that the laminar distribution
could be compared under identical conditions for each animal and experimental group. Quantitative
analysis of immunogold labelling for GABAB1 was performed on five different dendritic compartments
of granule cells in the molecular layer of the DG and in the somata of granule cells in the granule
cell layer. The dendritic compartments analysed were the main dendritic shaft (primary dendrites),
spiny branchlets (secondary dendrites) and dendritic spines. Secondary dendrites were identified
based on their small diameter and the presence of at least one emerging spine from the dendritic
shaft. Dendritic spines were considered as such if: (i) they emerged from a dendritic shaft, or (ii) they
opposed an axon terminal. Axon terminals were identified based on: (i) the presence of an active zone
(AZ) facing a postsynaptic density (PSD), recognised by an accumulation of intramembrane particles
(IMPs), on the opposing exoplasmic-face (E-face) of a spine or dendrite with spines; or (ii) the presence
of synaptic vesicles on their cross-fractured portions. Non-specific background labelling was measured
on E-face structures surrounding the measured P-faces. Images of the identified compartments were
selected randomly over the entire dendritic tree of granule cells and then captured with an ORIUS
SC1000 CCD camera (Gatan, Munich, Germany). The area of the selected profiles and the number
of immunoparticles were measured using our GPDQ software [34]. Immunoparticle densities were
presented as mean ± SEM between animals. Statistical comparisons were performed with GraphPad
software (San Diego, CA, USA).
4.6. Quantification and Analysis of Pre-Embedding Immunogold Data
To establish the relative abundance of GABAB1 immunoreactivity in different compartments of
granule cells between the two genotypes, pre-embedding immunogold immunohistochemistry was
carried out [64]. Briefly, for each of three adult animals, three samples of tissue were obtained for the
preparation of embedding blocks, thus using in total nine blocks. To minimise false negatives, electron
microscopic serial ultrathin sections were cut close to the surface of each block, as immunoreactivity
decreased with depth. We estimated the quality of immunolabelling by always selecting areas with
optimal gold labelling at approximately the same distance from the cutting surface. Randomly selected
areas were then photographed from the selected ultrathin sections and used with final magnification
between 30,000 and 50,000 ×. Quantification of immunogold labelling was carried out in reference
areas of the DG totalling approximately 2500 µm2. We counted immunoparticles identified in each
reference area and present in different subcellular compartments: dendritic spines, dendritic shafts,
and axon terminals. The data were expressed as a percentage of immunoparticles in each subcellular
compartment, both in the plasma membrane and at intracellular sites.
Finally, it is worth mentioning that neuronal loss is only observed adjacent to plaques in the
APP/PS1 mouse model [10]. It should be noted that both in mouse models of AD and in AD patients,
neurons in contact with Aβ plaques suffer alterations in the morphology and number of dendritic spine,
with destroyed tissue in dystrophic neurites [66–69], as well as in synaptic transmission [55,67,68,70,71].
To avoid this situation, our quantitative analysis was performed in Aβ plaque-free regions of the DG.
Thus, the density values expressed as immunoparticles/µm2 in the APP/PS1 mice represent a genuine
reduction in GABAB receptors in different compartments of granule cells, regardless of any possible
neuronal and/or synaptic loss.
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4.7. Controls
To test method specificity in the procedures for electron microscopy, the primary antibody was
either omitted or replaced with 5% (v/v) normal serum of the species of the primary antibody, resulting
in total loss of the signal. For the pre-embedding technique, labelling patterns were also compared with
those obtained with Calbindin (polyclonal rabbit anti-Calbindin D-9k CB9; Swant, Marly, Switzerland);
only the antibodies against GABAB1 consistently labelled the plasma membrane.
4.8. Data analysis
Statistical analyses for morphological data were performed using SigmaStat Pro (Jandel Scientific)
and data were presented as mean ± SEM unless indicated otherwise. Statistical significance was
defined as p < 0.05. The statistical evaluation of the immunogold densities was performed using the
two-way ANOVA test, and further compared with the Bonferroni post-hoc test.
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